Page last updated: 2024-12-04

bremazocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bremazocine: potent, log-acting opiate kappa-agonist & centrally acting analgesic; RN given refers to (2R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107697
CHEMBL ID1797687
MeSH IDM0088738
PubMed CID1223
CHEMBL ID350384
SCHEMBL ID11246286
MeSH IDM0088738

Synonyms (24)

Synonym
PDSP2_001419
PDSP1_001435
bremazocine
CHEMBL1797687 ,
bdbm50347177
unii-isf76m2dbe
bremazocine [inn]
83829-76-9
dl-bremazocine
(+-)-bremazocine
2,6-methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-
isf76m2dbe ,
L000925
CHEMBL350384 ,
6-ethyl-3-(1-hydroxy-cyclopropylmethyl)-11,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
bdbm50013388
bremazocine(-)
SCHEMBL11246286
Q4960506
(+/-)-bremazocine
DTXSID50868536
1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
2,6-methano-3-benzazocin-8-ol,6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl
2,6-methano-3-benzazocin-8-ol,6-ethyl-1,2,3,4,5,6-hexahydro-3-[(1-hydroxycyclopropyl)methyl]-11,11-dimethyl-, (2r)-

Research Excerpts

Dosage Studied

Kappa agonist, bremazocine, bound (in order of decreasing affinity) to the kappa approximately equal to mu greater than delta binding sites. Pre-exposure to ICI174864 also induced a shift to the left in dose-response curves for bremzocine and TIPP.

ExcerptRelevanceReference
" At all pretreatment times, the antinociceptive dose-response lines for these kappa agonists were displaced to the right to various degrees in a parallel fashion; an increasing rightward displacement of the U69,593 and bremazocine antinociceptive dose-response lines was observed at 1 and 3 days after a single nor-BNI pretreatment, with a gradual return toward the control level at later times after pretreatment."( Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.
Horan, P; Porreca, F; Taylor, J; Yamamura, HI, 1992
)
0.28
" A dose-response study demonstrated that the maximum growth hormone release was obtained with 10 micrograms/kg while higher doses were less or not effective."( The growth hormone secretory response to fentanyl in rat: an involvement of mu type receptors.
Buydens, P; Finné, E; Govaerts, J; Matton, A; Vanhaelst, L, 1990
)
0.28
" The agonist, bremazocine, bound (in order of decreasing affinity) to the kappa approximately equal to mu greater than delta binding sites, and it's pharmacological effects appeared in the dosage range of kappa and mu binding."( In vivo binding of benzomorphans to mu, delta and kappa opioid receptors: comparison with urine output in the rat.
Richards, ML; Sadée, W, 1985
)
0.27
" But a number of kappa agonists, including bremazocine, tifluadom, ethylketocyclazocine, ketocyclazocine, U-50,488 and Win 42,610 all depressed contractions, producing parallel dose-response curves."( Profile of activity of kappa receptor agonists in the rabbit vas deferens.
Hayes, A; Kelly, A, 1985
)
0.27
", delayed nociceptive reaction on a 55 degrees C hot-plate with a dose-response curve not readily fitting a single straight line; this effect was antagonized by high doses of naloxone."( Bremazocine induces antinociception, but prevents opioid-induced constipation and catatonia in rats and precipitates withdrawal in morphine-dependent rats.
Gambino, MC; Petrillo, P; Tavani, A, 1984
)
0.27
"6-fold rightward shift of the U69,593 dose-response line."( Lack of cross-tolerance between U69,593 and bremazocine suggests kappa-opioid receptor multiplicity in mice.
Horan, PJ; Porreca, F, 1993
)
0.29
" Pre-exposure to ICI174864 also induced a shift to the left in dose-response curves for bremazocine and TIPP."( Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist.
Azzi, M; Bouvier, M; deLéan, A; Piñeyro, G; Schiller, PW, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (22)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit alpha-6Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit gamma-2Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit deltaMus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit alpha-2Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit alpha-3Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit gamma-3Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.00150.00010.729810.0000AID148624
Delta-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00150.00030.38877.0000AID149626
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.00080.00010.813310.0000AID148624; AID152405
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)0.00100.00020.75218.0140AID148624; AID149626; AID152405
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00120.00030.71237.0700AID147958
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)0.00080.00001.201110.0000AID148624; AID152405
Kappa-type opioid receptorHomo sapiens (human)Ki0.00000.00000.362410.0000AID488649
Gamma-aminobutyric acid receptor subunit beta-1Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit alpha-1Mus musculus (house mouse)IC50 (µMol)0.00050.00000.03690.0740AID152405
Gamma-aminobutyric acid receptor subunit beta-3Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00180.00020.660310.0000AID148992
Gamma-aminobutyric acid receptor subunit alpha-5Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit piMus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit alpha-4Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit thetaMus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
Gamma-aminobutyric acid receptor subunit gamma-1Mus musculus (house mouse)IC50 (µMol)0.00050.00000.00030.0005AID152405
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID603728Displacement of [3H]U69593 from kappa opioid receptor in guinea pig cerebellum homogenate by scintillation counting2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
AID603731Selectivity ratio of Ki for mu opioid receptor in guinea pig forebrain homogenate to Ki for kappa opioid receptor in guinea pig cerebellum homogenate2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
AID603727Selectivity ratio of Ki for delta opioid receptor in guinea pig forebrain homogenate to Ki for kappa opioid receptor in guinea pig cerebellum homogenate2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
AID603729Displacement of [3H]NTI from delta opioid receptor in guinea pig forebrain homogenate by scintillation counting2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
AID603730Displacement of [3H]DAMGO from mu opioid receptor in guinea pig forebrain homogenate by scintillation counting2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
AID148624Inhibition of 0.5 nM [3H]bremazocine binding to guinea pig brain membrane opioid receptors1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.
AID147960Inhibition of opioid receptor kappa by displacing 0.5 nM [3H]bremazocine in guinea pig brain membrane1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay.
AID149445Inhibition of 0.5 nM [3H]- Bremazocine binding to Opioid receptor mu 1 of bovine striatum membrane1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID488650Selectivity ratio of Ki for mu opioid receptor to kappa opioid receptor2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.
AID149626Inhibition of [3H]DPDPE binding to guinea pig brain membrane Opioid receptor delta 1 at 1.0 nM1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.
AID152405In vitro binding affinity against Opioid receptors from bovine caudate nucleus determined in presence of [3H]- bremazocine (0.5 nM)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Conjugate addition ligands of opioid antagonists. Methacrylate esters and ethers of 6 alpha- and 6 beta-naltrexol.
AID488649Binding affinity to kappa opioid receptor2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.
AID148992inhibition of 1.0 nM [3H]- DAGO binding to guinea pig brain membrane opioid receptor mu1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.
AID148475Inhibition of total opioid receptor by displacing 0.5 nM [3H]bremazocine in guinea pig brain membrane1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay.
AID147958Displacement of 0.5 nM [3H]bremazocine from guinea pig brain membrane opioid receptor kappa with 100 nM DAGO and 100 nM DPDPE1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.
AID149630Inhibition of Opioid receptor delta 1 by displacing 1 nM [3H]DPDPE in guinea pig brain membrane1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay.
AID148993Inhibition of opioid receptor mu by displacing 1 nM [3H]DAGO in guinea pig brain membrane1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (304)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990141 (46.38)18.7374
1990's112 (36.84)18.2507
2000's44 (14.47)29.6817
2010's7 (2.30)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.52 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews5 (1.55%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other318 (98.45%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]